First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
The patent encompasses
"The issuance of this patent signals what we believe is the first in a series of worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology," said
About ctDNA Target Selector™ Technology
The "switch-blocker" technology covered by
In clinical validation studies,
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the
outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, our ability to obtain additional patents in the future covering our proprietary liquid biopsy technology, and the perceived benefits of our proprietary liquid biopsy technology, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/first-us-patent-issued-for-biocepts-target-selector-oncogene-mutation-enrichment-and-detection-liquid-biopsy-ctdna-platform-300566466.html
SOURCE
News Provided by Acquire Media